MCID: PYR039
MIFTS: 47

Peyronie Disease

Categories: Rare diseases, Reproductive diseases

Aliases & Classifications for Peyronie Disease

MalaCards integrated aliases for Peyronie Disease:

Name: Peyronie Disease 57 76 53 55 73
Penile Curvature 53

Characteristics:

OMIM:

57
Inheritance:
male-limited, autosomal dominant


Classifications:



External Ids:

OMIM 57 171000
MedGen 42 C0030848
UMLS 73 C0030848

Summaries for Peyronie Disease

NIH Rare Diseases : 53 Peyronie disease is a connective tissue disorder characterized by a plaque, or hard lump, that forms within the penis. Affected individuals may experience painful, curved erections which can make make normal sexual intercourse impossible. Symptoms may appear suddenly or develop gradually. While the painful erections for most men resolve over time, the scar tissue and curvature may remain. Some cases appear to resolve spontaneously. The exact cause of Peyronie's disease is not known.

MalaCards based summary : Peyronie Disease, also known as penile curvature, is related to peyronie's disease and impotence. An important gene associated with Peyronie Disease is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Pathways in cancer. The drugs Acetylcholine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and prostate, and related phenotypes are abnormality of the genitourinary system and dupuytren contracture

Wikipedia : 76 Peyronie''s disease is a connective tissue disorder involving the growth of fibrous plaques in the soft... more...

Description from OMIM: 171000

Related Diseases for Peyronie Disease

Diseases in the Peyronie Disease family:

Peyronie's Disease

Diseases related to Peyronie Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 20)
# Related Disease Score Top Affiliating Genes
1 peyronie's disease 32.3 IFNA2 TGFB1 TGFB3
2 impotence 30.1 NOS2 PDE5A
3 dupuytren contracture 11.1
4 ledderhose disease 11.1
5 hypospadias 10.6
6 duplication of urethra 10.1
7 giant hemangioma 10.1 IFNA2 TGFB1
8 spinal cord injury 10.0 NOS2 TGFB1
9 pulmonary edema 10.0
10 priapism 10.0
11 pneumoconiosis 9.9 SOD1 TGFB1
12 eales disease 9.9 NOS2 SOD1
13 tuberculoid leprosy 9.9 TGFB1 TGFB3
14 hypertrophic scars 9.9 TGFB1 TGFB3
15 ureteral obstruction 9.9 NOS2 TGFB1
16 keloids 9.9 TGFB1 TGFB3
17 sexual disorder 9.9
18 compartment syndrome 9.9
19 penile disease 9.9 IFNA2 PDE5A TGFB1
20 chagas disease 9.8 NOS2 TGFB1

Graphical network of the top 20 diseases related to Peyronie Disease:



Diseases related to Peyronie Disease

Symptoms & Phenotypes for Peyronie Disease

Symptoms via clinical synopsis from OMIM:

57
G U:
penile contracture

Limbs:
associated dupuytren contracture


Clinical features from OMIM:

171000

Human phenotypes related to Peyronie Disease:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the genitourinary system 32 HP:0000119
2 dupuytren contracture 32 HP:0005679

Drugs & Therapeutics for Peyronie Disease

Drugs for Peyronie Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 2 51-84-3 187
2
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
3
Chlorhexidine Approved, Vet_approved Phase 2 55-56-1 2713 9552079
4 Botulinum Toxins, Type A Phase 2
5 Peripheral Nervous System Agents Phase 2
6 abobotulinumtoxinA Phase 2
7 Cholinergic Agents Phase 2
8 Pharmaceutical Solutions Phase 2
9 Neurotransmitter Agents Phase 2
10 Acetylcholine Release Inhibitors Phase 2
11 onabotulinumtoxinA Phase 2
12 Botulinum Toxins Phase 2
13 Neuromuscular Agents Phase 2
14 Anti-Infective Agents, Local Phase 2
15 Anti-Infective Agents Phase 2
16 Dermatologic Agents Phase 2
17 Chlorhexidine gluconate Phase 2
18 Analgesics Phase 2
19 Disinfectants Phase 2
20 Anti-Arrhythmia Agents Phase 2
21 Anesthetics, Local Phase 2
22 Diuretics, Potassium Sparing Phase 2
23 Central Nervous System Depressants Phase 2
24 Sodium Channel Blockers Phase 2
25 Anesthetics Phase 2
26
Tocopherol Approved, Investigational Phase 1 1406-66-2 14986
27
Testosterone enanthate Approved Phase 1 315-37-7 9416
28
Testosterone Approved, Investigational Phase 1 58-22-0 6013
29
Methyltestosterone Approved Phase 1 58-18-4 6010
30
Testosterone undecanoate Approved, Investigational Phase 1 5949-44-0
31
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
34 Tocotrienol Investigational Phase 1 6829-55-6
35 Protective Agents Phase 1
36 Calciferol Phase 1
37 Tocopherols Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
39 Tocotrienols Phase 1
40 Micronutrients Phase 1
41 Antioxidants Phase 1
42 Hormone Antagonists Phase 1
43 Testosterone 17 beta-cypionate Phase 1
44 Hormones Phase 1
45 Bone Density Conservation Agents Phase 1
46 Androgens Phase 1
47 Anabolic Agents Phase 1
48 Vitamins Phase 1
49 Ergocalciferols Phase 1
50 Trace Elements Phase 1

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Treatment Response to Xiaflex for Men With Peyronie's Disease Recruiting NCT03774264 Phase 4 Xiaflex
2 Xiaflex® Plus Testosterone Treatment Pilot Study Protocol Recruiting NCT03815331 Phase 4 Xiaflex®;Aveed
3 Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response Recruiting NCT03767452 Phase 4 Xiaflex® 0.58 mg
4 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
5 A Study of AA4500 in Men With Peyronie's Disease Completed NCT01243411 Phase 3
6 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221597 Phase 3
7 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
8 An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Completed NCT02267460 Phase 3
9 H-22411: BOTOX® for Peyronie's Disease Unknown status NCT00812838 Phase 2 100 units of Botulinum Toxin Type A
10 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) Unknown status NCT01184586 Phase 2
11 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
12 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
13 Urethral Sterilization With Chlorhexidine Digluconate to Facilitate Primary Repair & Same-Session Implantation Recruiting NCT03614429 Phase 2 Chlorhexidine gel will be prepared according to an international product Instillagel®
14 Intracavernosal Injection of Botulinum Toxin Type A (50 and 100 Unit) in the Treatment of Erectile Dysfunction Enrolling by invitation NCT03355963 Phase 2
15 Clostridium Histolyticum Collagenase Injection for Urethral Disease Not yet recruiting NCT02948842 Phase 2 Clostridium Histolyticum Collagenase;Lidocaine
16 Peyronie's Disease Treatment Protocol Completed NCT02072018 Phase 1 H-100;Placebo
17 Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Completed NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
18 Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Completed NCT02395029 Phase 1
19 Management of Peyronie's Disease With Adipose Tissue Stem Cell Unknown status NCT02414308 Not Applicable Adipose tissue stem cell injection
20 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830 Not Applicable
21 Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease Completed NCT02298829 Subjects Previously Treated with AA4500
22 Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy Completed NCT00800813
23 Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease. Recruiting NCT03530540 Not Applicable
24 Penile Length Maintenance Post-Prostatectomy Recruiting NCT03500419 Not Applicable
25 Penile Length Restoration in Men With Diabetes Mellitus, Type II Recruiting NCT03756688 Not Applicable
26 Efficacy of Penile Traction Therapy Using a Novel Device Active, not recruiting NCT03389854 Not Applicable
27 Outcomes of Surgical Correction of Penile Curvature in Adult Not yet recruiting NCT03313986

Search NIH Clinical Center for Peyronie Disease

Genetic Tests for Peyronie Disease

Anatomical Context for Peyronie Disease

MalaCards organs/tissues related to Peyronie Disease:

41
Bone, Lung, Prostate, Small Intestine, Skin, Spinal Cord

Publications for Peyronie Disease

Articles related to Peyronie Disease:

(show top 50) (show all 204)
# Title Authors Year
1
Re: Clinical Experience with Penile Traction Therapy among Men Undergoing Collagenase Clostridium Histolyticum for Peyronie Disease. ( 29310171 )
2018
2
Separating the Wheat From the Chaff: An Evaluation of Readability, Quality, and Accuracy of Online Health Information for Treatment of Peyronie Disease. ( 29723588 )
2018
3
Penile Reconstructive Surgery in Peyronie Disease: Challenges in Restoring Normal Penis Size, Shape, and Function. ( 29623703 )
2018
4
A Novel Noninvasive Ultrasound Vibro-elastography Technique for Assessing Patients With Erectile Dysfunction and Peyronie Disease. ( 29548864 )
2018
5
Primary Treatment of Peyronie's Disease: A 55-yr-old Male with 45° Dorsal Penile Curvature and Good Erectile Function. ( 30369422 )
2018
6
Long-term Results of Ventral Penile Curvature Repair in Childhood. ( 29051007 )
2018
7
Reconstructive surgery for recurrent penile curvature. ( 29058072 )
2018
8
Re: An unanswered question in pediatric urology: the post pubertal persistence of prepubertal congenital penile curvature correction by tunical plication. ( 29244267 )
2018
9
REPLY BY THE AUTHORS: Re: An unanswered question in pediatric urology: the post pubertal persistence of prepubertal congenital penile curvature correction by tunical plication. ( 29244268 )
2018
10
Objective measurements of the penile angulation are significantly different than self-estimated magnitude among patients with penile curvature. ( 29570261 )
2018
11
Modified 16-Dot plication technique for correction of penile curvature: prevention of knot-related complications. ( 29736012 )
2018
12
Re: Objective Measurements of the Penile Angulation are Significantly Different than Self-Estimated Magnitude among Patients with Penile Curvature. ( 30227550 )
2018
13
Prevalence of penile curvature: a population-based cross-sectional study in metropolitan and rural cities in Australia. ( 30387224 )
2018
14
Impact of Camera Deviation on Penile Curvature Assessment Using 2D Pictures. ( 30415815 )
2018
15
Clinical Experience With Penile Traction Therapy Among Men Undergoing Collagenase Clostridium histolyticum for Peyronie Disease. ( 28347795 )
2017
16
Small Intestinal Submucosa Grafting for Peyronie Disease: Outcomes and Patient Satisfaction. ( 27825744 )
2017
17
Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease. ( 28554517 )
2017
18
Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease. ( 28502596 )
2017
19
Re: Factors Associated with Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients with Peyronie Disease. ( 29144914 )
2017
20
Self-reported Clinical Meaningfulness Early in the Treatment Course Predicts Objective Outcomes in Men Undergoing Collagenase Clostridium histolyticum Injections for Peyronie Disease. ( 28483591 )
2017
21
Re: Clinical Experience with Penile Traction Therapy among Men Undergoing Collagenase Clostridium histolyticum for Peyronie Disease. ( 28817884 )
2017
22
Correction of Residual Ventral Penile Curvature After Division of the Urethral Plate in the First Stage of a 2-Stage Proximal Hypospadias Repair. ( 28213855 )
2017
23
Re: Small Intestinal Submucosa Grafting for Peyronie Disease: Outcomes and Patient Satisfaction. ( 29059762 )
2017
24
Congenital prepubic sinus (an epispadiac variant of dorsal urethral duplication) with dorsal penile curvature in an adult man: a rare association. ( 28596205 )
2017
25
Patient-reported long-term sexual outcomes following plication surgery for penile curvature: A retrospective 58-patient study. ( 27867021 )
2017
26
Re: Do Adult Men with Untreated Ventral Penile Curvature Have Adverse Outcomes? ( 27979563 )
2017
27
Patient satisfaction with correction of congenital penile curvature. ( 29292041 )
2017
28
Partial Plaque Excision and Grafting With Collagen Fleece in Peyronie Disease. ( 26953837 )
2016
29
The Genetic Basis of Peyronie Disease: A Review. ( 27872008 )
2016
30
Shaeer's Corporal Rotation III: Shortening-Free Correction of Congenital Penile Curvature-The Noncorporotomy Technique. ( 26298209 )
2016
31
Do adult men with untreated ventral penile curvature have adverse outcomes? ( 26776946 )
2016
32
The Efficacy of Congenital Penile Curvature Repair in Preadolescent Males: Early Outcomes. ( 26845052 )
2016
33
Penile curvature: an update for management from 20 years experience in a high volume centre. ( 27103093 )
2016
34
Re: Evaluation of the Treatment of Congenital Penile Curvature including Psychosexual Assessment. ( 27186747 )
2016
35
Geometrical modified nesbit corporoplasty to correct different types of penile curvature: description of the surgical procedure based on geometrical principles and long-term results. ( 27511302 )
2016
36
Re: The Efficacy of Congenital Penile Curvature Repair in Preadolescent Males: Early Outcomes. ( 27845136 )
2016
37
Effects of Stem Cell Treatment in Human Patients With Peyronie Disease. ( 26414724 )
2015
38
Re: Corporoplasty Using Buccal Mucosa Graft in Peyronie Disease: Is it a First Choice? ( 26088238 )
2015
39
Corporoplasty using buccal mucosa graft in Peyronie disease: is it a first choice? ( 25582815 )
2015
40
Intralesional Injections for Early Peyronie Disease: Standardized Assessment and Analysis of Predictive Factors for Treatment Response. ( 26142583 )
2015
41
Intralesional Injection of Interferon-α2b Improves Penile Curvature in Men with Peyronie's Disease Independent of Plaque Location. ( 26144333 )
2015
42
Re: The STAGE technique (superficial tunica albuginea geometric-based excision) for the correction of biplanar congenital penile curvature. ( 25617297 )
2015
43
Rotation of the corpora cavernosa for the treatment of congenital penile curvature. ( 25667175 )
2015
44
A new corporoplasty based on stratified structure of tunica albuginea for the treatment of congenital penile curvature - long-term results. ( 25914848 )
2015
45
Multiple urethral anomalies: Parameatal urethral cyst, penile curvature, incomplete hypospadiac anterior duplication of the urethra and distal hipospadias. ( 26029298 )
2015
46
Evaluation of the Treatment of Congenital Penile Curvature Including Psychosexual Assessment. ( 26139203 )
2015
47
Editorial Comment on "Evaluation of the Treatment of Congenital Penile Curvature including Psycho-Sexual Assessment". ( 26255808 )
2015
48
The Egydio geometrical procedure for managing penile curvature using a single relaxing incision: A single-centre experience with 330 patients. ( 26609449 )
2015
49
Lingual mucosal graft in treatment of Peyronie disease. ( 25283703 )
2014
50
The anti-inflammatory and antifibrosis effects of anthocyanin extracted from black soybean on a Peyronie disease rat model. ( 25156514 )
2014

Variations for Peyronie Disease

Expression for Peyronie Disease

Search GEO for disease gene expression data for Peyronie Disease.

Pathways for Peyronie Disease

Pathways related to Peyronie Disease according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 IFNA2 NOS2 TGFB1 TGFB3
2 12.34 IFNA2 NOS2 TGFB1 TGFB3
3
Show member pathways
12.18 IFNA2 NOS2 PDE5A SOD1 TGFB1 TGFB3
4
Show member pathways
11.95 IFNA2 TGFB1 TGFB3
5
Show member pathways
11.88 NOS2 TGFB1 TGFB3
6 11.8 NOS2 TGFB1 TGFB3
7 11.66 TGFB1 TGFB3
8 11.64 TGFB1 TGFB3
9 11.61 TGFB1 TGFB3
10 11.6 TGFB1 TGFB3
11 11.57 TGFB1 TGFB3
12 11.57 NOS2 SOD1
13 11.51 IFNA2 TGFB1
14 11.51 IFNA2 NOS2 TGFB1 TGFB3
15
Show member pathways
11.5 TGFB1 TGFB3
16 11.45 NOS2 SOD1
17 11.42 TGFB1 TGFB3
18 11.42 NOS2 TGFB1 TGFB3
19
Show member pathways
11.39 NOS2 SOD1
20 11.37 TGFB1 TGFB3
21 11.34 TGFB1 TGFB3
22 11.31 NOS2 TGFB1
23 11.31 TGFB1 TGFB3
24 11.28 TGFB1 TGFB3
25 11.27 TGFB1 TGFB3
26 11.23 TGFB1 TGFB3
27
Show member pathways
11.18 NOS2 PDE5A
28 11.18 NOS2 TGFB1 TGFB3
29
Show member pathways
11.15 NOS2 SOD1
30 11.1 NOS2 TGFB3
31 11.09 IFNA2 NOS2
32 10.99 TGFB1 TGFB3
33
Show member pathways
10.93 TGFB1 TGFB3
34 10.89 TGFB1 TGFB3
35 10.48 NOS2 PDE5A

GO Terms for Peyronie Disease

Cellular components related to Peyronie Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.33 SOD1 TGFB1 TGFB3
2 platelet alpha granule lumen GO:0031093 9.26 TGFB1 TGFB3
3 collagen-containing extracellular matrix GO:0062023 9.13 IFNA2 TGFB1 TGFB3
4 secretory granule GO:0030141 8.8 SOD1 TGFB1 TGFB3

Biological processes related to Peyronie Disease according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.84 IFNA2 TGFB1 TGFB3
2 positive regulation of apoptotic process GO:0043065 9.8 SOD1 TGFB1 TGFB3
3 cytokine-mediated signaling pathway GO:0019221 9.78 IFNA2 NOS2 TGFB1
4 negative regulation of gene expression GO:0010629 9.73 IFNA2 NOS2 TGFB1
5 aging GO:0007568 9.69 SOD1 TGFB1 TGFB3
6 female pregnancy GO:0007565 9.68 TGFB1 TGFB3
7 wound healing GO:0042060 9.67 TGFB1 TGFB3
8 response to organic substance GO:0010033 9.67 SOD1 TGFB1
9 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.67 TGFB1 TGFB3
10 regulation of cell proliferation GO:0042127 9.67 NOS2 TGFB1 TGFB3
11 positive regulation of MAP kinase activity GO:0043406 9.66 PDE5A TGFB1
12 cell development GO:0048468 9.65 TGFB1 TGFB3
13 regulation of MAPK cascade GO:0043408 9.65 TGFB1 TGFB3
14 SMAD protein signal transduction GO:0060395 9.65 TGFB1 TGFB3
15 response to hypoxia GO:0001666 9.65 NOS2 TGFB1 TGFB3
16 inner ear development GO:0048839 9.64 TGFB1 TGFB3
17 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.64 TGFB1 TGFB3
18 positive regulation of cell division GO:0051781 9.63 TGFB1 TGFB3
19 positive regulation of epithelial to mesenchymal transition GO:0010718 9.62 TGFB1 TGFB3
20 negative regulation of T cell proliferation GO:0042130 9.62 PDE5A TGFB1
21 positive regulation of protein secretion GO:0050714 9.61 TGFB1 TGFB3
22 mammary gland development GO:0030879 9.6 TGFB1 TGFB3
23 response to progesterone GO:0032570 9.59 TGFB1 TGFB3
24 digestive tract development GO:0048565 9.58 TGFB1 TGFB3
25 positive regulation of bone mineralization GO:0030501 9.58 TGFB1 TGFB3
26 face morphogenesis GO:0060325 9.57 TGFB1 TGFB3
27 positive regulation of collagen biosynthetic process GO:0032967 9.55 TGFB1 TGFB3
28 cell-cell junction organization GO:0045216 9.54 TGFB1 TGFB3
29 platelet degranulation GO:0002576 9.54 SOD1 TGFB1 TGFB3
30 superoxide metabolic process GO:0006801 9.52 NOS2 SOD1
31 positive regulation of superoxide anion generation GO:0032930 9.46 SOD1 TGFB1
32 positive regulation of SMAD protein signal transduction GO:0060391 9.43 TGFB1 TGFB3
33 salivary gland morphogenesis GO:0007435 9.4 TGFB1 TGFB3
34 response to laminar fluid shear stress GO:0034616 9.32 TGFB1 TGFB3
35 negative regulation of macrophage cytokine production GO:0010936 9.26 TGFB1 TGFB3
36 frontal suture morphogenesis GO:0060364 9.16 TGFB1 TGFB3
37 ossification involved in bone remodeling GO:0043932 8.96 TGFB1 TGFB3
38 regulation of epithelial to mesenchymal transition involved in endocardial cushion formation GO:1905005 8.62 TGFB1 TGFB3

Molecular functions related to Peyronie Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 IFNA2 TGFB1 TGFB3
2 transforming growth factor beta receptor binding GO:0005160 9.32 TGFB1 TGFB3
3 type I transforming growth factor beta receptor binding GO:0034713 9.16 TGFB1 TGFB3
4 type II transforming growth factor beta receptor binding GO:0005114 8.96 TGFB1 TGFB3
5 type III transforming growth factor beta receptor binding GO:0034714 8.62 TGFB1 TGFB3

Sources for Peyronie Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....